COMPANY **BACKGROUNDER**

Adaptimmune's Vision and Mission

Adaptimmune is driven by a mission to transform the lives of people with cancer by designing and delivering cell therapies. The Company plans to file for a biologics license application (BLA) in 2022 for its TCR T-cell therapy targeting MAGE-A4, **afamitresgene autoleucel** (afami-cel, previously ADP-A2M4), for the treatment of synovial sarcoma and myxoid/round cell liposarcoma (MRCLS). If approved, it would be the first TCR T-cell therapy and the Company's first therapy on the market.

"We are building the cell therapy company of the future for people with cancer. Over the next five years, we plan to deliver two marketed products, one in sarcoma and one in gastroesophageal cancers, and file two additional BLAs in other solid tumor indications. We also plan to develop a robust autologous and allogeneic clinical pipeline that takes us towards the ultimate goal of curative and mainstream cell therapies for people with cancer."

ADRIAN RAWCLIFFE
CHIEF EXECUTIVE OFFICER

About the Company

- Adaptimmune is a leader in cell therapy, with clinical trials ongoing for **T-cell receptor-based T-cell therapies** in multiple solid tumor indications.
- The core of Adaptimmune's clinical cell therapy technology is its proprietary engineering of **T-cell receptors** (TCRs), known as **SPEAR** (Specific Peptide Enhanced Affinity Receptor) T-cells, to target solid tumors.
- Adaptimmune has a strong pipeline of affinity-enhanced T-cell therapies, which harness the body's own immune system to find and destroy cancer cells.
- These engineered TCRs are introduced into a patient's own T-cells, which are then given back to the patient to **fight cancer,** all of which is made possible through a robust manufacturing process.
- There have been **durable responses in synovial sarcoma,** and initial responses in head and neck, lung, esophagogastric junction, and melanoma cancers, with SPEAR T-cells targeting the cancer antigen MAGE-A4. There is also early data with a SPEAR T-cell targeting AFP for people with liver cancer.
- Through research done at its UK facility, Adaptimmune is working to design and develop a **deep preclinical pipeline of next-generation cell therapy approaches,** new targets, HLA-independent TCRs, Tumor Infiltrating Lymphocytes, and stem-cell derived allogeneic cell therapies that could be available "on-demand."

"I'm thrilled with the responses in a broad range of tumors with our programs targeting MAGE-A4 and AFP. I am confident that we will be able to identify more indications for late-stage development as more patients are treated in our trials."

ELLIOT NORRY
CHIEF MEDICAL OFFICER

Current Clinical Trials

PROGRAM	THERAPY	PRECLINICAL	PHASE 1	PHASE 2/3
MAGE-A4	afamitresgene autoleucel (afami-cel, previously ADP-A2M4)	★ →	**Phase 1 Trial** Multiple tumors* ★ → **Radiation sub study*** Multiple tumors** →	**SPEARHEAD-1** Synovial sarcoma, MRCLS → RMAT & ODD; EU ODD and Prime **SPEARHEAD-2** Head & neck Combo with pembro →
	ADP-A2M4CD8	★ →	**SURPASS** Focus on lung, esophageal, head & neck and bladder cancers →	**SURPASS-2** Esophageal and EGJ cancers *Initiating in 2021* →
AFP	ADP-A2AFP	★ →	**Phase 1 trial** Hepatocellular carcinoma →	
Allogeneic/ HiT		→		★ **Completed stage**

* Bladder, Melanoma, Head & Neck, Ovarian, Non-small cell lung cancer (NSCLC), Esophageal, Gastric, Synovial sarcoma, MRCLS
** Site specific protocol amendment with MD Anderson Cancer Center MRCLS=myxoid/round cell liposarcoma; EGJ: esophagogastric junction cancers

Clinical Trial Data in Synovial Sarcoma

At the Connective Tissue Oncology Society (CTOS) 2020 annual meeting, Adaptimmune presented key data from its Phase 1 clinical trial targeting MAGE-A4 for the subset of patients with synovial sarcoma

- Seven out of 16 patients (44%) had confirmed partial responses (PRs) per RECIST criteria, with disease control in 15 patients (94%).[1]
- There was a median duration of response of 28 weeks (range: 12-72+ weeks) with two PRs that were ongoing beyond 72 weeks at the time of data cut-off.[2]
- Eleven out of 16 patients were alive at data cut-off and median overall survival had not been reached.[3]
- **The response rate was considerably superior**[4] to response rates observed with available second-line therapies in synovial sarcoma.

Registrational data from the **SPEARHEAD-1 Phase 2 clinical trial** will be presented at ASCO 2021 on **June 4th at 1:30 p.m.-4:30 p.m. EDT (abstract #11504).** The data was announced on May 19th.

Meet the Senior Leadership Team

ADRIAN RAWCLIFFE
Chief Executive Officer

JOANNA BREWER
Senior Vice President,
Allogeneic Research

JOHN LUNGER
Chief Patient Supply
Officer

ELLIOT NORRY
Chief Medical Officer

**DENNIS WILLIAMS,
PHARM.D**
Senior Vice President,
Late Stage Development

**WILLIAM (BILL)
BERTRAND**
Chief Operating Officer

MARK DUDLEY
Senior Vice President,
Early Stage Development

KAREN MILLER, PH.D.
Senior Vice President,
Pipeline Research

**HELEN TAYTON-
MARTIN**
Chief Business Officer

GAVIN WOOD
Chief Financial Officer

References

1 Adaptimmune Therapeutics plc. Released November 19, 2020.

2 Adaptimmune Therapeutics plc. Released November 19, 2020.

3 Adaptimmune Therapeutics plc. Released November 19, 2020.

4 Pollack S, et al. Cancer Medicine. 2020;9:4593–4602; Seto T, et al Med. Sci. 2019, 7, 48; van der Graaf WT, et al. 2012, Lancet, 379(9829), 1879-1886